Monoclonal antibodies in the treatment of lymphoma;Anticorps monoclonaux dans le traitement des lymphomes

Revue du Praticien

Volumn 52, Issue 9, 2002, Pages 982-985

  Mounier, Nicolas ^a   Gisselbrecht, Christian ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DIFTITOX; DOXORUBICIN; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY DAB IL2 PLUS DENILEUKIN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

AUTOGRAFT; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG MECHANISM; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; RADIOISOTOPE DISTRIBUTION; REMISSION; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOCONJUGATES; LYMPHOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 0036570992     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
2. Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
3. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
4. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
5. A European phase II study of Rituximab (Chimeric anti-CD20 monoclonal anti-body) for patients with newly-diagnosed mantle cell lymphoma, and previously treated mantle cell lymphoma, immunocytoma & small lymphocytic lymphoma
6. Rituximab (Anti-CD 20 monoclonal antibody) for the treatment of patients with relapsing of refractory aggressive lymphoma: A multicenter phase II study
7. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
8. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
9. Epratuzumab (HLL2, anti-CD22 humanized monoclonal antibody) is an active and well tolerated therapy for refractory/relapsed diffuse large B-cell on non-Hodgkin's lymphoma (NHL)
10. Treatment in Low-Grade non Hodgkin's Lymphoma. CAMPATH-IH monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
11. Multicenter study of CAMPATH-IH in patients with chronic lymphocytic leukaemia (B-CLL) refractory to fludarabine
12. Iodine-131-Anti-BI radioimmunotherapy for B-Cell lymphoma
13. Radioimmunotherapy with Iodine (131) tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience
14. Results of a randomized study of BexxarTM (Tositumomab and Iodine I 131 Tositumomab) vs. unlabeled Tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL)
15. Final results of of a randomized controlled study of the Zevalin radioimunotherapy regimen versus a standard courses of Rituximab immunotherapy for B-cell NHL
16. Chimeric fusion protein DAB(486)IL2 in refractory mycosis fongoides and the sezary syndrom: Correlation of activity and IL2 receptor expression in a phase II study
17. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy
18. Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
19. CHOP plus Rituximab with CHOP chemotherapy in elderly patients with diffuse large B-Cell lymphoma
20. Follow-up of relapsed B-cell lymphoma patients treated with Iodine-131-Labeled anti-CD20 antibody and autologous stemcell rescue